{"id":513629,"date":"2021-07-15T09:38:12","date_gmt":"2021-07-15T13:38:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/"},"modified":"2021-07-15T09:38:12","modified_gmt":"2021-07-15T13:38:12","slug":"freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/","title":{"rendered":"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SAN DIEGO<\/span>, <span class=\"xn-chron\">July 15, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0The <i>Frequency Therapeutics, Inc.<\/i> class action lawsuit charges Frequency Therapeutics and its CEO with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Frequency Therapeutics common stock between <span class=\"xn-chron\">November 16, 2020<\/span> and <span class=\"xn-chron\">March 22, 2021<\/span>, inclusive (the &#8220;Class Period&#8221;).\u00a0 The <i>Frequency Therapeutics<\/i> class action lawsuit was commenced on <span class=\"xn-chron\">June 3, 2021<\/span> in the District of <span class=\"xn-location\">Massachusetts<\/span> and is captioned <i>Evans v. Frequency Therapeutics, Inc.<\/i>, No. 21-cv-10933.\u00a0 A similar lawsuit, captioned <i>Hingston v. Frequency Therapeutics, Inc.<\/i>, No. 21-cv-11040, is also pending in the District of <span class=\"xn-location\">Massachusetts<\/span>.<\/p>\n<p>\n        <b>If you suffered substantial losses and wish to serve as lead plaintiff of the <i>Frequency Therapeutics<\/i> class action lawsuit, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3228446-1&amp;h=3171975362&amp;u=https%3A%2F%2Fwww.rgrdlaw.com%2Fcases-frequency-therapeutics-inc-class-action.html&amp;a=please+provide+your+information+by+clicking+here\" rel=\"nofollow noopener\">please provide your information by clicking here<\/a>.\u00a0 You can also contact attorney <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3228446-1&amp;h=4064214445&amp;u=https%3A%2F%2Fwww.rgrdlaw.com%2Fattorneys-Juan-Carlos-Sanchez.html&amp;a=J.C.+Sanchez\" rel=\"nofollow noopener\">J.C. Sanchez<\/a> of Robbins Geller by calling 800\/449-4900 or via e-mail at <a target=\"_blank\" href=\"mailto:jsanchez@rgrdlaw.com\" rel=\"nofollow noopener\">jsanchez@rgrdlaw.com<\/a>.\u00a0 Lead plaintiff motions for the <i>Frequency Therapeutics<\/i> class action lawsuit must be filed with the court no later than <span class=\"xn-chron\">August 2, 2021<\/span>.<\/b>\n      <\/p>\n<p>\n        <b>CASE ALLEGATIONS: <\/b>The <i>Frequency Therapeutics<\/i> class action lawsuit alleges that, shortly after launching the Phase FX-322 2a trial, Frequency Therapeutics and its Chief Executive Officer, defendant <span class=\"xn-person\">David L. Lucchino<\/span>, learned that the Phase 2a trial results revealed no discernable difference between FX-322 and the placebo.\u00a0 The <i>Frequency Therapeutic<\/i>s class action lawsuit further alleges that, while Frequency Therapeutics&#8217; stock price remained artificially inflated, defendant Lucchino sold over 350,000 Frequency Therapeutics shares, pocketing over <span class=\"xn-money\">$10.5 million<\/span>.<\/p>\n<p>On <span class=\"xn-chron\">March 23, 2021<\/span>, Frequency Therapeutics disclosed deeply disappointing interim Phase 2a results, revealing that subjects with mild to moderate severe sensorineural hearing loss did not demonstrate improvements in hearing measures versus placebo.\u00a0 On this news, Frequency Therapeutics&#8217; stock price fell by nearly 78%, damaging investors.<\/p>\n<p>\n        <b>THE LEAD PLAINTIFF PROCESS:<\/b> The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Frequency Therapeutics common stock during the Class Period to seek appointment as lead plaintiff in the <i>Frequency Therapeutics<\/i> class action lawsuit.\u00a0 A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.\u00a0 A lead plaintiff acts on behalf of all other class members in directing the <i>Frequency Therapeutics<\/i> class action lawsuit.\u00a0 The lead plaintiff can select a law firm of its choice to litigate the <i>Frequency Therapeutics<\/i> class action lawsuit.\u00a0 An investor&#8217;s ability to share in any potential future recovery of the <i>Frequency Therapeutics<\/i> class action lawsuit is not dependent upon serving as lead plaintiff.<\/p>\n<p>\n        <b>ABOUT ROBBINS GELLER RUDMAN &amp; DOWD LLP<\/b>:\u00a0With 200 lawyers in 9 offices nationwide, Robbins Geller Rudman &amp; Dowd LLP is the largest U.S. law firm representing investors in securities class actions.\u00a0 Robbins Geller attorneys have obtained many of the largest shareholder recoveries in history, including the largest securities class action recovery ever \u2013 <span class=\"xn-money\">$7.2 billion<\/span> \u2013 in <i>In re Enron Corp. Sec. Litig.<\/i>\u00a0 The 2020 ISS Securities Class Action Services Top 50 Report ranked Robbins Geller first for recovering <span class=\"xn-money\">$1.6 billion<\/span> for investors last year, more than double the amount recovered by any other securities plaintiffs&#8217; firm.\u00a0 Please visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3228446-1&amp;h=509565018&amp;u=https%3A%2F%2Fwww.rgrdlaw.com%2Ffirm.html&amp;a=https%3A%2F%2Fwww.rgrdlaw.com%2Ffirm.html\" rel=\"nofollow noopener\">https:\/\/www.rgrdlaw.com\/firm.html<\/a> for more information.<\/p>\n<p>Attorney advertising.<br \/>Past results do not guarantee future outcomes.<br \/>Services may be performed by attorneys in any of our offices.<\/p>\n<p>Contact:<br \/>Robbins <span class=\"xn-person\">Geller Rudman<\/span> &amp; Dowd LLP<br \/>655 W. Broadway, <span class=\"xn-location\">San Diego<\/span>, CA\u00a0 92101 <br \/>J.C. Sanchez, 800-449-4900<br \/><a target=\"_blank\" href=\"mailto:jsanchez@rgrdlaw.com\" rel=\"nofollow noopener\">jsanchez@rgrdlaw.com<\/a><\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA43666&amp;sd=2021-07-15\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit-301334084.html\">https:\/\/www.prnewswire.com\/news-releases\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit-301334084.html<\/a><\/p>\n<p>SOURCE  Robbins Geller Rudman &amp; Dowd LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA43666&amp;Transmission_Id=202107150935PR_NEWS_USPR_____LA43666&amp;DateId=20210715\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO, July 15, 2021 \/PRNewswire\/ &#8212;\u00a0The Frequency Therapeutics, Inc. class action lawsuit charges Frequency Therapeutics and its CEO with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Frequency Therapeutics common stock between November 16, 2020 and March 22, 2021, inclusive (the &#8220;Class Period&#8221;).\u00a0 The Frequency Therapeutics class action lawsuit was commenced on June 3, 2021 in the District of Massachusetts and is captioned Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933.\u00a0 A similar lawsuit, captioned Hingston v. Frequency Therapeutics, Inc., No. 21-cv-11040, is also pending in the District of Massachusetts. If you suffered substantial losses and wish to serve as lead plaintiff of the Frequency Therapeutics class action lawsuit, please provide your &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-513629","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, July 15, 2021 \/PRNewswire\/ &#8212;\u00a0The Frequency Therapeutics, Inc. class action lawsuit charges Frequency Therapeutics and its CEO with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Frequency Therapeutics common stock between November 16, 2020 and March 22, 2021, inclusive (the &#8220;Class Period&#8221;).\u00a0 The Frequency Therapeutics class action lawsuit was commenced on June 3, 2021 in the District of Massachusetts and is captioned Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933.\u00a0 A similar lawsuit, captioned Hingston v. Frequency Therapeutics, Inc., No. 21-cv-11040, is also pending in the District of Massachusetts. If you suffered substantial losses and wish to serve as lead plaintiff of the Frequency Therapeutics class action lawsuit, please provide your &hellip; Continue reading &quot;FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-15T13:38:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA43666&amp;sd=2021-07-15\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit\",\"datePublished\":\"2021-07-15T13:38:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/\"},\"wordCount\":579,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA43666&amp;sd=2021-07-15\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/\",\"name\":\"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA43666&amp;sd=2021-07-15\",\"datePublished\":\"2021-07-15T13:38:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA43666&amp;sd=2021-07-15\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=LA43666&amp;sd=2021-07-15\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, July 15, 2021 \/PRNewswire\/ &#8212;\u00a0The Frequency Therapeutics, Inc. class action lawsuit charges Frequency Therapeutics and its CEO with violations of the Securities Exchange Act of 1934 and seeks to represent purchasers of Frequency Therapeutics common stock between November 16, 2020 and March 22, 2021, inclusive (the &#8220;Class Period&#8221;).\u00a0 The Frequency Therapeutics class action lawsuit was commenced on June 3, 2021 in the District of Massachusetts and is captioned Evans v. Frequency Therapeutics, Inc., No. 21-cv-10933.\u00a0 A similar lawsuit, captioned Hingston v. Frequency Therapeutics, Inc., No. 21-cv-11040, is also pending in the District of Massachusetts. If you suffered substantial losses and wish to serve as lead plaintiff of the Frequency Therapeutics class action lawsuit, please provide your &hellip; Continue reading \"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-15T13:38:12+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA43666&amp;sd=2021-07-15","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit","datePublished":"2021-07-15T13:38:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/"},"wordCount":579,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA43666&amp;sd=2021-07-15","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/","name":"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA43666&amp;sd=2021-07-15","datePublished":"2021-07-15T13:38:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA43666&amp;sd=2021-07-15","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA43666&amp;sd=2021-07-15"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/freq-investor-alert-investors-with-substantial-losses-have-opportunity-to-lead-the-frequency-therapeutics-inc-class-action-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"FREQ INVESTOR ALERT: Investors With Substantial Losses Have Opportunity to Lead the Frequency Therapeutics, Inc. Class Action Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/513629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=513629"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/513629\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=513629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=513629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=513629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}